Kymera Therapeutics KYMR Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $357.01M+197% | $120.26M+9.4% | $109.97M+60.8% | $68.4M+42.6% | ||
| $491.27M+33.3% | $368.49M+39.1% | $264.92M-21.8% | $338.77M-14.1% | ||
| $5.8M+0.1% | $5.79M-0.3% | $5.81M-5.2% | $6.13M+0.2% | ||
| $22.94M+6.6% | $21.52M+84.4% | $11.67M+20.2% | $9.71M+11.4% | ||
| —— | $947K-74.8% | $3.76M+48.3% | $2.54M+1,779% | ||
| $871.21M+70.7% | $510.27M+25.9% | $405.32M-3.4% | $419.42M-7.1% | ||
| $43.18M-14.4% | $50.46M+4.8% | $48.13M+261% | $13.33M+12.2% | ||
| $42.35M-10.7% | $47.41M-10.5% | $52.95M+494% | $8.91M-5.5% | ||
| $9.11M+367% | $1.95M-7.9% | $2.12M-29.8% | $3.02M+49.2% | ||
| $771.16M+113% | $362.16M+490% | $61.43M-59.7% | $152.33M+21.7% | ||
| $1.74B+78.2% | $978.04M+69.9% | $575.76M-4.5% | $603.13M-0.5% | ||
| $4.02M-33.0% | $5.99M-15.3% | $7.08M+63.2% | $4.34M+8.2% | ||
| $242K+8.5% | $223K-57.4% | $524K+72.9% | $303K+32.9% | ||
| $22.93M+68.9% | $13.58M-64.2% | $37.88M+7.4% | $35.26M-42.9% | ||
| $1.82M+19.6% | $1.52M+18.9% | $1.28M-9.3% | $1.41M+23.7% | ||
| $11.94M+3.0% | $11.59M+129% | $5.07M+99.9% | $2.54M+3.0% | ||
| $1.82M+19.6% | $1.52M+18.9% | $1.28M-9.3% | $1.41M+23.7% | ||
| $11.44M— | $0-100% | $16.77M-40.1% | $28M-28.7% | ||
| $83.21M+22.8% | $67.77M-20.9% | $85.69M+20.1% | $71.34M-22.9% | ||
| $67.03M-7.4% | $72.42M-6.0% | $77.03M+534% | $12.15M-8.2% | ||
| $3.28M-12.5% | $3.74M+45.2% | $2.58M-2.9% | $2.65M+16.5% | ||
| $78.98M-6.0% | $84.02M+2.3% | $82.1M+459% | $14.68M-6.4% | ||
| $1.46M-34.3% | $2.23M+71.1% | $1.3M+4.4% | $1.25M+9.3% | ||
| $163.15M+14.6% | $142.42M-21.2% | $180.79M+60.0% | $112.98M-22.8% | ||
| $0— | $0— | —— | —— | ||
| $8K+14.3% | $7K+16.7% | $6K0.0% | $6K+20.0% | ||
| $2.64B+66.1% | $1.59B+71.8% | $926.27M+5.4% | $878.88M+27.5% | ||
| -$1.07B-41.3% | -$754.61M-42.2% | -$530.75M-38.3% | -$383.79M-67.6% | ||
| $1.8M+221% | -$1.49M-169% | -$552K+88.8% | -$4.95M-650% | ||
| $1.58B+89.0% | $835.62M+112% | $394.97M-19.4% | $490.15M+6.6% | ||
| $1.74B+78.2% | $978.04M+69.9% | $575.76M-4.5% | $603.13M-0.5% | ||
| $491.27M+33.3% | $368.49M+39.1% | $264.92M-21.8% | $338.77M-14.1% | ||
| $9.11M+367% | $1.95M-7.9% | $2.12M-29.8% | $3.02M+49.2% | ||
| $42.35M-10.7% | $47.41M-10.5% | $52.95M+494% | $8.91M-5.5% | ||
| $771.16M+113% | $362.16M+490% | $61.43M-59.7% | $152.33M+21.7% | ||
| $42.35M-10.7% | $47.41M-10.5% | $52.95M+494% | $8.91M-5.5% | ||
| $9.11M+367% | $1.95M-7.9% | $2.12M-29.8% | $3.02M+49.2% | ||
| $42.35M-10.7% | $47.41M-10.5% | $52.95M+494% | $8.91M-5.5% | ||
| $9.11M+367% | $1.95M-7.9% | $2.12M-29.8% | $3.02M+49.2% | ||
| $11.44M— | $0-100% | $16.77M-40.1% | $28M-28.7% | ||
| $42.27M+21.2% | $34.87M+3.0% | $33.86M+23.1% | $27.5M+19.7% | ||
| $42.27M+21.2% | $34.87M+3.0% | $33.86M+23.1% | $27.5M+19.7% | ||
| $242K+8.5% | $223K-57.4% | $524K+72.9% | $303K+32.9% | ||
| $11.44M— | $0-100% | $16.77M-40.1% | $28M-28.7% | ||
| $11.44M— | $0-100% | $16.77M-40.1% | $28M-28.7% | ||
| $84.07M-5.8% | $89.28M+3.9% | $85.95M+359% | $18.74M-1.9% | ||
| $2.64B+66.1% | $1.59B+71.8% | $926.27M+5.4% | $878.88M+27.5% | ||
| $8K+14.3% | $7K+16.7% | $6K0.0% | $6K+20.0% | ||
| $0— | $0— | —— | —— | ||
| $1.82M+19.6% | $1.52M+18.9% | $1.28M-9.3% | $1.41M+23.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Kymera Therapeutics's total assets?
- Kymera Therapeutics (KYMR) holds $1.7B in total assets, up 81.8% year over year.
- How much debt does Kymera Therapeutics have?
- Kymera Therapeutics carries $82.2M in total debt against $1.5B of shareholders' equity, a debt-to-equity ratio of 0.05.
- How much cash does Kymera Therapeutics have?
- Kymera Therapeutics holds $144.1M in cash and equivalents.
- Can Kymera Therapeutics cover its short-term obligations?
- Its current ratio is 10.81 — current assets exceed current liabilities.
- Where does Kymera Therapeutics's balance sheet data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
